Earlier Detection. Better Outcomes.

A clinically validated blood test designed to improve Lyme disease detection across all stages of disease.

Validated on 1,000+ clinical samples from the Unites States and Europe.

Why Current Testing Falls Short

Current Lyme disease tests rely on the body's antibody response, which may not be detectable during early infection. As a result, many patients receive negative test results despite having active disease when treatment is most effective.

ChatGPT Image Jun 7, 2026, 01_54_35 PM.png

Why LYMESEEK™ Is Different

Current Testing

Relies on antibody response

Often misses early infection

Multi-step testing

Variable performance

LYMESEEK™

Uses propriety biomarkers & machine learning

Designed to detect Lyme across all stages

Single blood draw

>90% accuracy

How LYMESEEK Works

LYMESEEK™ combines proprietary biomarkers with machine learning to identify disease patterns that traditional testing may miss.

Copy of AcesDiagnostic May 21 2026 Version (2).png

Clinical Validation

LYMESEEK™ has been validated on more than 1,000 clinical samples from the U.S. and Europe, demonstrating high accuracy across all stages of Lyme disease while maintaining compatibility with existing laboratory infrastructure.

1,000+ Samples

Evaluated on more than 1,000 clinical samples

>90% Accuracy

Validated across all stages of Lyme disease

U.S. & E.U. Validation

Demonstrated performance across U.S. and E.U. populations

Benefits

PATIENTS
Earlier Answers

Early diagnosis improves outcomes and reduces the risk of long-term complications.

PHYSICIANS
Greater Diagnostic Confidence

Accurate, objective results support earlier treatment decisions.

CLINICAL LABORATORIES
Runs On Existing Equipment

Requires no special equipment allowing for seamless workflow integration

Economic Impact

Why Earlier Diagnosis Matters

Independent health-economic analysis indicates that earlier and more accurate Lyme disease diagnosis has the potential to reduce unnecessary testing, specialist referrals, and overall healthcare costs.

Boston Strategic Partners projects LYMESEEK™ could reduce Lyme-related healthcare costs by $3.2 Billion annually through earlier diagnosis and intervention.

Advancing Towards Commercialization

DISCOVERY PHASE

2014-2023

Identified propriety biomarkers and AI-driven diagnostic approach.

TEST DEVELOPMENT

2024

Assay design and algorithm development

VERIFICATION & VALIDATION

2025-2026

Validated on 1,000+ clinical samples across U.S. and E.E. populations.

CLINICAL TRIALS & REGULATORY SUBMISSION

2026-2027

Preparing for pivotal FDA clinical trials and regulatory review.

COMMERCIAL LAUNCH

2027

Clinical laboratory partnerships and market introduction.

Interested in Learning More?

We welcome conversations with investors, clinical laboratory partners, healthcare organizations, and industry leaders who share our vision of improving Lyme disease diagnosis.